ArticleClinicoEconomics and outcomes research : CEOR2021

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain.

Maria Mareque et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.